Image credit: Freepik
Lotte Biologics has entered a late-stage to commercial contract manufacturing partnership with a U.S.-based global biopharmaceutical company. The term of the contract extends until middle of 2030.
The partnership covers a late-stage Phase 3 program that is advancing into multiple new indications, and extends to commercial supply following potential regulatory approvals. By aligning with its partner's meaningful pipeline expansion into new therapeutic areas, Lotte Bilogics will be playing a pivotal role in supporting patient access to innovative medicines.
The partnership reaffirms the company's manufacturing capabilities and quality leadership in the global market, while highlighting the geographical advantages of its U.S. manufacturing footprint.
Leveraging its dual-site operations at Syracuse NY and Songdo, Korea under one unified quality system, the company continues to expand collaboration with U.S.-based firms and broaden its global client base by providing proximity to key biopharma hubs, reliable supply, and flexible response to dynamic demand needs.
